- Home
- CNTA vs LGND Comparison
CNTA vs LGND Comparison
Compare CNTA & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | LGND |
|---|---|---|
| Founded | 2020 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | 68 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTA | LGND |
|---|---|---|
| Price | $39.51 | $204.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $42.00 | ★ $245.86 |
| AVG Volume (30 Days) | ★ 3.9M | 193.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | $1.50 |
| Revenue Next Year | N/A | $18.28 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $93.58 |
| 52 Week High | $40.26 | $227.92 |
Technical Indicators
Market Signals| Indicator | CNTA | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 76.56 | 53.79 |
| Support Level | $24.80 | $194.45 |
| Resistance Level | N/A | $207.72 |
| Average True Range (ATR) | 1.33 | 8.46 |
| MACD | 1.25 | -0.49 |
| Stochastic Oscillator | 94.93 | 63.62 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.